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‘No drug should be discarded until it has been tried in 
systemic sclerosis’. A phrase of this sort can still be found 
in many textbooks and reviews on systemic sclerosis 
(SSC), but the time has come to raise our expectations. 
Th  e study by Bosello and colleagues [1] in this issue of 
Arthritis Research & Th  erapy provides tantalizing data on 
the eﬀ   ects of rituximab in nine patients with diﬀ  use 
cutaneous systemic sclerosis (dcSSc) nonresponsive to 
cyclophos  phamide. A single treatment course induced a 
consistent and sustained improvement of skin thickening, 
disease activity, and functional ability, notably in the 
seven patients with early disease. In those with organ 
involvement, function remained stable. Re  treat  ment was 
given in one patient with clinical relapse and pre-
emptively in two patients who had rapid recon  stitution of 
B cells. Th   e clinical eﬀ  ects were paralleled by biological 
eﬀ   ects, including depletion of circulating B cells, and 
changes in serum levels of interleukin-6 (IL-6) and BAFF 
(B-cell activating factor of tumor necrosis factor family). 
IL-6 has a role in ﬁ  brogenesis, and the reduction in IL-6 
following rituximab treatment may be one of the 
explanations for the eﬀ  ect on skin ﬁ  brosis as found in this 
and other recent studies. Several cell types produce IL-6, 
including B cells, macrophages, and stromal cells, and so 
the eﬀ  ect of rituximab on IL-6 in dcSSc could be due to 
direct depletion of IL-6-producing B cells or, more likely, 
indirect eﬀ  ects of B-cell depletion on IL-6 production by 
stromal cells or macrophages or both.
Th   e study extends the results of other recently 
published papers reporting clinical beneﬁ  t of rituximab 
therapy [2-4]. Together, they conﬁ  rm earlier predictions 
that B cells might be an attractive target in SSc [5,6]. 
What is most striking in these studies is the prospect that 
this drug has a more favorable risk-to-beneﬁ  t ratio of 
treatment when compared with other therapies such as 
imatinib, cyclophosphamide, or immunoablative therapy 
and autologous stem cell transplantation. No serious 
adverse events attributable to rituximab were reported in 
any of the rituximab studies, and toxicity seemed mild at 
worst. In contrast, remarkable eﬀ  ects on skin thickening 
were found in three of the four studies, including a small 
placebo-controlled, randomized trial [1,3,4]. All three, in 
contrast to the ﬁ  rst published study, in which a single 
treatment course failed to induce a marked eﬀ  ect on skin 
thickening [2], involved either optional or preplanned 
repeat treatment. In one case, repeat treatment was 
successfully continued at 6-month intervals for 2 years 
[7]. Th  e one randomized trial and a number of case 
reports also showed a beneﬁ  cial  eﬀ   ect of rituximab 
treatment on SSc lung disease [3,8,9].
So what’s the price? First, rituximab (and any other 
biological for that matter) does not come cheap, 
especially when repeat treatment is necessary. As a result 
of this and in the absence of consensus or guidelines on 
the use of biologicals in connective tissue diseases such 
as SSc, access is problematic in many health care systems. 
Second, although rituximab is generally well tolerated (as 
exempliﬁ  ed in the SSc patients treated so far), studies in 
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© 2010 BioMed Central Ltdother conditions have suggested an increased, albeit low, 
risk of progressive multifocal leukoencephalopathy in 
patients on concomitant or previous immunosuppressive 
therapy. Of note, numbers of circulating B cells and 
serum concentrations of IgM dropped signiﬁ  cantly in the 
study by Bosello and colleagues [1], consistent with data 
in rheumatoid arthritis, but long-term safety data on 
repeat treatment in SSc are lacking. In the context of the 
poor prognosis of dcSSc, the risk of infection may be one 
worth taking in patients with few eﬀ  ective  treatment 
options. Th  ird, rituximab is not eﬀ  ective in all patients 
and, in one case, reportedly had divergent eﬀ  ects  on 
diﬀ   erent disease manifestations [10]. In this patient, 
rituximab had an eﬀ   ect on myositis, but not on skin 
thickening. At present, it is not possible to predict which 
SSc patient will respond to rituximab, as illustrated by 
the obser  vation that rituximab was also eﬀ  ective in SSc 
patients whose skin biopsies did not contain detectable 
B-cell numbers. Whether this points to sampling error or 
a pathogenetic role of B cells at other sites (for example, 
lymph nodes) remains to be determined. Clearly, improved 
prediction models are needed.
Th  e combined results of recent rituximab studies 
warrant adequately powered clinical trials in larger 
patient groups to compare safety and eﬃ   cacy  of 
rituximab versus placebo or rituximab versus conven-
tional therapy (for example, cyclophosphamide, at the 
moment still the considered the gold standard for severe 
SSc). Long-term outcome analyses are essential to evalu-
ate feasibility, safety, and eﬃ   cacy of (repeat) treat  ment. 
Criteria for retreatment should be developed once 
eﬃ   cacy of a single treatment course has been proven. To 
understand whether and how rituximab aﬀ  ects  the 
diﬀ  erent patho  genetic pathways implicated in SSc, com-
pre  hensive biomarker studies should be part of the 
clinical trial protocol. Such trials require a multicenter, 
maybe even a multinational, approach and concerted 
action from specialists, patients, and funding agencies. 
Any such trial will be costly and complex and demand 
stamina and creativity to deal with study methodology 
issues resulting from its low incidence, heterogeneity in 
clinical presentations, and natural disease course. With a 
potentially eﬀ   ective and relatively safe drug in hand, 
however, the time has come to try to break the deadlock 
in SSc treatment.
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